(Q33691338)

28 July 2017

title

Identifying priority medicines policy issues for New Zealand: a general inductive study (English)

1 reference

28 July 2017

0 references

1

Zaheer-Ud-Din Babar

1 reference

28 July 2017

Susan Francis

2

1 reference

28 July 2017

publication date

28 May 2014

1 reference

28 July 2017

1 reference

28 July 2017

volume

4

1 reference

28 July 2017

issue

5

1 reference

28 July 2017

page(s)

e004415

1 reference

Targeted therapy in rare cancers--adopting the orphans

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039830

A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039830

International variability in the reimbursement of cancer drugs by publically funded drug programs

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039830

The need for worldwide policy and action plans for rare diseases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039830

A qualitative evaluation of general practitioners' perceptions regarding access to medicines in New Zealand.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039830

Priority-setting processes for medicines: the United Kingdom, Australia and New Zealand.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039830

The Trans-Pacific Partnership Agreement: challenges for Australian health and medicine policies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039830

Comments on "Simoens, S. Health economic assessment: a methodological primer. Int. J. Environ. Res. Public Health 2009, 6, 2950-2966"-New Zealand in fact has no cost-effectiveness threshold

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039830

Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039830

Access to high cost medicines in Australia: ethical perspectives

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039830

"Price management" and its impact on hospital pharmaceutical expenditure and the availability of medicines in New Zealand hospitals.

21 June 2018

1 reference

https://api.crossref.org/works/10.1136%2FBMJOPEN-2013-004415

The impact of pharmaceutical cost containment policies on the range of medicines available and subsidized in Finland and New Zealand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBMJOPEN-2013-004415

Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBMJOPEN-2013-004415

How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBMJOPEN-2013-004415

Key informants' perceptions of how pharmac operates in New Zealand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBMJOPEN-2013-004415

Ethnic differences in access to prescription medication because of cost in New Zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBMJOPEN-2013-004415

Funding and access to high cost medicines in public hospitals in Australia: decision-makers' perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBMJOPEN-2013-004415

Access to high cost drugs in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBMJOPEN-2013-004415

Orphan drugs for rare diseases: is it time to revisit their special market access status?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBMJOPEN-2013-004415

Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBMJOPEN-2013-004415

Cardiovascular health in New Zealand: areas of concern and targets for improvement in 2008 and beyond

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039830

Response from PHARMAC: difficult choices

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039830

Will Pharmac become a victim of its own success?

30 October 2018

1 reference

12 December 2020

How New Zealand has contained expenditure on drugs

1 reference

12 December 2020

Access to new medicines in New Zealand compared to Australia

1 reference

12 December 2020

New Zealand agency comes under pressure to pay more for drugs

1 reference

12 December 2020

Evaluating pharmacists' views, knowledge, and perception regarding generic medicines in New Zealand

1 reference

12 December 2020

Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand

1 reference

12 December 2020

Do pharmaceutical score cards give us the answers we seek?

1 reference

12 December 2020

Assessing the economic challenges posed by orphan drugs

1 reference

12 December 2020

Response to PHARMAC on Access to new medicines in New Zealand compared to Australia

1 reference

12 December 2020

Which orphans will find a home? The rule of rescue in resource allocation for rare diseases

1 reference

12 December 2020

Tier 4 drugs and the fraying of the social compact

1 reference

12 December 2020

The challenges of orphan drugs and orphan diseases: real and imagined

1 reference

12 December 2020

10.1136/BMJOPEN-2013-004415

Identifiers

DOI

1 reference

28 July 2017

1 reference

28 July 2017

1 reference